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Abstract
Tumour angiogenesis is defined by an anarchic vasculature and irregularities in alignment of endothelial cells. These struc-
tural abnormalities could explain the variability in distribution of nanomedicines in various tumour models. Then, the main 
goal of this study was to compare and to characterize the tumour vascular structure in different mouse models of melanoma 
tumours (B16F10 and SK-Mel-28) and in human melanomas from different patients. Tumours were obtained by subcutaneous 
injection of  106 B16F10 and 3.106 SK-Mel-28 melanoma cells in C57BL/6 and nude mice, respectively. Tumour growth was 
evaluated weekly, while vasculature was analysed through fluorescent labelling via CD31 and desmin. Significant differ-
ences in tumour growth and mice survival were evidenced between the two melanoma models. A fast evolution of tumours 
was observed for B16F10 melanoma, reaching a tumour size of 100  mm3 in 7 days compared to SK-Mel-28 which needed 
21 days to reach the same volumes. Important differences in vascularization were exposed between the melanoma models, 
characterized by a significant enhancement of vascular density and a significant lumen size for mice melanoma models com-
pared to human. Immunostaining revealed irregularities in endothelium structure for both melanoma models, but structural 
differences of vasculature were observed, characterized by a stronger expression of desmin in SK-Mel-28 tumours. While 
human melanoma mainly develops capillaries, structural irregularities are also observed on the samples of this tumour model. 
Our study revealed an impact of cell type and tumour progression on the structural vasculature of melanoma, which could 
impact the distribution of drugs in the tumour environment.
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Introduction
Angiogenesis, a critical step in tumorigenesis, is defined as 
cellular processes leading to the formation of new blood ves-
sels from pre-existing vasculature (Carmeliet and Jain 2000). 
Many solid tumours are known to stimulate angiogenesis 
to create vasculature required for their growth, spread, and 
metastasis (Hanahan and Weinberg 2000, 2011).
As for all solid tumours, melanoma growth needs a high 
angiogenic activity, an important step in melanoma metas-
tasis (Elder et al. 1996; Tuthill and Reed 2007). Vasculari-
zation is characterized by a monolayer of endothelial cells 
surrounded by one or more layers of smooth muscle cells 
and supporting cells such as pericytes, whose localization 
is on the basal lamina of the vascular endothelium. Angio-
genesis is characterized by an angiogenic switch, i.e., an 
imbalance between pro-angiogenic factors, such as VEGF, 
fibroblast growth factors (FGF-1, FGF-2), platelet-derived 
growth factor (PDGF-B and PDGF-C), and anti-angiogenic 
factor production, such as thrombospondin-1 (TSP-1) 
(Folkman 2002). Furthermore, tumour vasculature is char-
acterized by tortuous ramifications, heterogeneity in their 
diameter, distribution and density (Baluk et al. 2005). This 
anarchic vasculature gives rise to heterogeneous blood flow, 
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defined by poor perfusion of plasma and hypoxic regions in 
tumours (Jain and Baxter 1988). Thereby, in tumour ves-
sels, it has been reported some irregularities in alignment of 
endothelial cells and a lack of pericyte cells (Armulik et al. 
2011). Furthermore, perivascular smooth muscle is often 
lacking in tumour vessels, making them poorly reactive to 
normal vasoregulation (Chan et al. 1984). These changes 
enhance vascular permeability through an increase in gap 
formation between endothelial cells (0.1–3 µm in diameter) 
that promotes release of macromolecules into extravascular 
compartment (Danquah et al. 2011; McDonald et al. 1999; 
Matsumura and Maeda 1986).
Improved efficacy of treatments through modulation of 
tumour endothelium has been largely described in melanoma 
mice models (Bolkestein et al. 2016; Duncan et al. 2013). 
However, despite numerous preclinical studies, only few 
studies attempt to show the interest of the modification of 
tumour endothelium in clinical trial (Stirland et al. 2013): 
no study has been focused on the evaluation of the vascu-
lar structure in human tumours, compared to mice models. 
Therefore, this study aims to analyse the vascular structure 
of different melanomas from human and mice models to 
determine differences and correlations between them.
Materials and methods
SK‑Mel‑28 and B16F10 melanoma cell culture
The SK-Mel-28 human melanoma cell line, obtained from 
ATCC (LGC Promochem, Molsheim, France), and B16F10 
mouse melanoma cell line (gift from University of Brussels) 
were grown in RPMI-1640 medium (Lonza, Verviers, Bel-
gium) supplemented with 10% foetal bovine serum (Lonza, 
Verviers, Belgium), 10 units of penicillin, 10 mg of strepto-
mycin, 25 µg/mL of amphotericin B (Sigma-Aldrich, Saint 
Louis, USA), and 1% non-essential amino acids (Lonza). 
Cell lines were cultured according to ATCC protocol and 
maintained at 37 °C in a humidified atmosphere with 5% 
 CO2.
In vivo tumour development
Ethical approval
All procedures involving animals, including the breeding 
protocols, were conducted in accordance with protocols 
approved by the ethical committee of the University of 
Angers and the regional ethics committee on animal test-
ing. Furthermore, these experiments were approved by 
the ethical committee of the University of Angers and the 
regional ethics committee on animal testing (Authorization 
no. 01315.01 12/2013). Furthermore, animal experiments 
were carried out in strict accordance with recommendations 
in the guidelines of the Code for Methods and Welfare Con-
siderations in Behavioral Research with Animals (Directive 
2010/63/UE).
Orthotopic model of B16F10 melanoma
C57BL/6 mice have been housed at the university animal 
facility (Service Commun d’Animalerie Hospitalo-Univer-
sitaire—Université d’Angers, France). Syngenic, allograft 
model of melanoma has been obtained by injecting subcu-
taneously a suspension of 1.106 B16F10 melanoma cells 
in 100 µL of RPMI into the right flank of mice. Tumour 
size and tumour volume were monitored until the end of 
the protocol and have been estimated using the formula: 
V = 휋∕6 × L ×W
2 (L length and W width). At the end of the 
protocol, animals have been sacrificed and tumours were 
removed, frozen in isopentane, and stored at − 80 °C.
Orthotopic model of SK‑Mel‑28 melanoma
Female nude NMRI mice (Janvier SAS, Le Genest Saint 
Isle, France) have been housed at the university animal facil-
ity. Tumour-bearing mice were prepared by injecting subcu-
taneously a suspension of 3.106 SK-Mel-28 melanoma cells 
in 100 µL of RPMI into the right flank of mice.
Tumour size and tumour volume were monitored until 
the end of the protocol and they have been estimated using 
the formula: V = 휋∕6 × L ×W2 (L length and W width). At 
the end of the protocol, animals have been sacrificed and 
tumours were removed, frozen in isopentane and stored at 
− 80 °C.
Growth rate measurement and survival
Tumour volume, for each mouse, has been measured at dif-
ferent timepoints. Thereby, the tumour growth rate was cal-
c u l a t e d  a c c o r d i n g  t o  t h e  f o r m u l a : 
(tumour volume at given day −tumour volume of previousmeasure)
number of days between measures
.
Immunostaining
Mice tumour samples
Frozen tumours were cut into 10 µm sections using Cry-
otome (CM3050D, Leica, Glattbrugg, Switzerland), and 
placed onto microscopic slides (Starfrost). Sections were 
air-dried for 1 h, rehydrated for 15 min in phosphate buff-
ered saline (PBS), fixed by incubation at 4 °C for 10 min in 
4% paraformaldehyde/PBS pH 7.4 and permeabilized with 
0.02% Triton X-100. Non-specific binding has been blocked 
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by incubation in PBS containing 4% bovine serum albumin 
(BSA) and 10% normal goat serum (NGS).
Sections were then incubated with CD31 (BD Bio-
sciences, San Jose, CA, USA, 1/200 diluted) and/or desmin 
(Dako Denmark A/S, 1/200 diluted) primary antibodies 
overnight at 4 °C (antibodies have been tested and validated 
on both mouse and human models). After washing with 
PBS, samples were treated with a secondary antibody in 5% 
BSA in PBS for 1 h at room temperature (Table 1). Nuclei 
were counter stained with 4′,6-diamidino-2-phenylindole 
(DAPI, Sigma-Aldrich Co.).
Sections were then visualized by confocal microscopy 
(confocal laser microscope TCS SP8, Leica, Glattbrugg, 
Switzerland, equipped with 50 mW diode laser) (Clere 
et al. 2010).
Size of vessel lumens was measured using the Image J 
Software. Vessel lumens were determined by absence of 
nuclei surrounded by endothelial cells. Area of vessels was 
calculated using the formula = 휋 × R × r . Lumen sizes were 
then classed on a power 10 scale to separate vessels by class 
size and expressed in function of the percentage of vessels 
measured by tumours.
Human tumour samples
The material consisted of a retrospective cohort of mela-
noma samples from 8 patients. All patients provided written 
informed consent and the study was approved by the local 
ethic committee and registered under the CNIL#1278197. 
5 µm paraffine embedded tissues were done and processed 
for immunohistochemistry on a Bond III system from Leica. 
Antibodies used were: anti-CD31 (1/160. clone J770A from 
Dako) and anti-desmin (1/200. Clone D33 from Dako). 
Details about patients are summarized in Table 1.
Vessel density and size measurement
The vessel density was assessed according to literature 
(Hansen et al. 2004). Immunostained tumours were analysed 
at low magnificent (10×) with a confocal laser microscope 
(TCS SP8, Leica), or a Leica DMR mounted with Scion 
CFW-1612C digital color camera (Scion Corporation). 
Numerous fields of the tumours were pictured, and all ves-
sels were counted using the Image J Software. Micro-vessel 
density was determined as the number of vessels per  mm2.
Statistical analysis
Results are expressed as boxplot. Each box represents 50% 
of the distribution (interquartile range: 25th percentile− 75th 
percentile). Median is marked as a black line in each box. 
Extending lines from boxes show minimum and maximum 
values. Outlier data are plot as black circles. Statistical anal-
ysis was performed using a Kruskal–Wallis test followed by 
a Dunn’s post-Hoc test with a Hochberg correction using the 
R software (R Foundation, Austria) with the PMCR package. 
The level of significance was set at p < 0.05. Survival rate 
has been assessed with the Kaplan–Meier method. The sur-
vival probability at any particular time is calculated, over a 
p e r i o d  t i m e ,  b y  t h e  f o r m u l a : 
(number of alive subjects at the starting point − number of subjects died)
number of alive subjects at the starting point
.
Results
B16F10 melanoma model grows faster 
than SK‑Mel‑28 tumour
Injection of B16F10 melanoma cells in mice induced a 
detectable tumour with a volume of 100  mm3 within 7 days 
after xenograft, whereas SK-Mel-28 cells required 21 days 
to induce a detectable tumour with the same volume. Fur-
thermore, it should be noted a difference in the duration of 
the experimental protocols. Thus, the growth of syngenic 
B16F10-allografted tumour is maximal after 19 days, while 
tumours induced by SK-Mel-28 cells grew for 49 days. At 
the end of the protocol, the average volume of B16F10-
allografted and SK-Mel-28-xenografted tumours was of 
Table 1  Patient clinical 
characteristics Patient # Sex Age at the time of surgery
Sample type (stage at diagnosis) Systemic treat-
ment at the time of 
surgery
1 M 76 Superficial spreading melanoma (stage I) None
2 M 71 Superficial spreading melanoma (stage I) None
3 M 78 Superficial spreading melanoma (stage I) None
4 M 51 Nodular melanoma (stage IV) None
5 F 88 Nodular melanoma (stage III) None
6 F 58 Nodular melanoma (stage IV) None
7 M 42 Nodular melanoma (stage II) None
8 M 48 Lymph node melanoma metastasis (stage III) None
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4018.47 ± 1179.82 and 430.00 ± 44.60  mm3, respectively 
(Table 2).
B16F10 melanoma model enhances mice mortality 
in comparison with SK‑Mel‑28 model
In B16F10-melanoma model, analysis of the survival of 
tumour-bearing mice revealed a first mortality of 17% and 
a second mortality of 16% after 13 and 17 days following 
tumour cell xenograft, respectively. No mortality has been 
observed in SK-Mel-28-tumour-bearing mice during the pro-
tocol. All mice have been sacrificed at day 49 corresponding 
to the end of the protocol (Fig. 1). Log-rank test analysis 
showed a significant difference in the survival curve between 
mice allografted with B16F10 cells and mice xenografted 
with SK-Mel-28 melanoma cells.
Analysis of vascular density in mice and human 
melanoma models
Microscopy observations of each tumour revealed an 
enhancement of CD31 staining in both B16F10-allografted 
tumour model (Fig. 2a) and human melanoma (Fig. 2c) in 
comparison with SK-Mel-28-xenografted melanoma model 
(Fig. 2b). This observation has been confirmed by the analy-
sis of tumour vascular density (expressed by the number 
of vessels per  mm2) which was significantly enhanced in 
B16F10-tumour model (20.52 vessels/mm2) compared 
to SK-Mel-28 melanoma model (9.05 vessels/mm2). No 
difference of vascular density has been found in human 
melanoma (11.68 vessels/mm2) in comparison with other 
mice models (Fig. 2d).
To confirm these first observations, analysis of the 
vessel number according to the area of their lumen has 
been realized by microscopy observations on each model. 
Thus, small vessels (area between 10 and  102 µm2) and 
vessels with medium area (between  102 and  103 µm2) were 
significantly (p < 0.05) enhanced in human tumours in 
comparison with B16F10 and SK-Mel-28 mice tumours. 
No difference has been found in the percentage of ves-
sels with lumen size between  103 and  104 µµ2 whatever 
the tumour models. Finally, vessels whose area is com-
prised between  104 and  105 µm2 were mainly found in 
murine tumours with, in particular, a significant increase 
(p < 0.05) in SK-Mel-28 model compared to human 
tumours (Fig. 3).
Expression of CD31 and desmin in mice and human 
melanoma models
The distribution pattern of CD31 and desmin was different 
according to the tumour models. A diffuse and low expres-
sion of both CD31 and desmin has been observed in tumours 
from B16F10 melanoma model (Fig. 4a, b). Furthermore, 
irregularities in endothelium structure have been found in 
SK-Mel-28 tumours confirmed by low and discontinuous 
CD31 expression at the periphery of the vessel lumen. More-
over, a stronger expression of desmin has been reported in 
these last samples (Fig. 4c, d). A diffuse and low expression 
of desmin has been found in human tumours (Fig. 4e).
Discussion
Tumour vascular endothelium constitutes a barrier more 
or less permeable to endogenous mediators or to the mol-
ecules used for therapeutic purposes. The present study 
provides evidence that, depending on melanoma tumour 
model, many structural and functional differences have 
been observed in tumour vascular endothelium. Thus, 
while tumour growth is faster in B16F10 than in SK-
Mel-28 melanoma model, vascular density in B16F10 
tumour model is significantly enhanced compared to 
SK-Mel-28 and human tumours. Furthermore, while ves-
sels from human melanoma present lumen size between 
Table 2  Characteristics of 
tumour growth in B16F10-
allografted and SK-Mel-28-
xenografted mice
B16F10 SK-Mel-28
Time to reach a volume of 100  mm3 (days) 7 21
Time to reach the end of the protocol (days) 19 49
Tumour volume at the end of the protocol  (mm3) 4018.47 ± 1179.82 430.00 ± 44.60
Fig. 1  Kaplan–Meier survival curves for mice with B16F10-allo-
grafted (n = 6) and SK-Mel-28-xenografted (n = 8) melanoma cells. P 
value (p = 0.00028) was derived from log-rank calculations
Author's personal copy
Journal of Cancer Research and Clinical Oncology 
1 3
10 and  103 μm2, B16F10 and SK-Mel-28 mice tumours 
develop significantly larger vessels with a lumen size com-
prised between  104 and  105 μm2. These last differences 
in vascularization were followed accompanied by struc-
tural abnormalities confirmed by a defect in CD31 and 
desmin expressions in B16F10 model, in comparison with 
Fig. 2  Confocal microscopy of B16F10 (a), SK-Mel-28 (b). Endothe-
lial cells were labelled with CD31 antibodies (green fluorescence), 
while nuclei were labelled with DAPI (Blue). Scale bar: 150  µm. c 
Analysis of human melanoma tumour. Endothelial cells were labelled 
with CD31 antibodies (brown staining) Scale bar: 150 µm. d Micro-
vascular density according to the study model. Results were presented 
in a boxplot, where bottom and top line of each box correspond to the 
25th and 75th percentiles, respectively *p ≤ 0.05. B16F10 n = 4, SK-
Mel-28 n = 8, human melanoma n = 8
Fig. 3  Area of vessels accord-
ing to the percentage of vessels 
measured in B16F10, SK-
Mel-28 and human melanoma. 
The significance value was 
calculated using a Kruskal–
Wallis test followed by a Dunn’s 
post-Hoc test with a Hochberg 
correction *p ≤ 0.05; **p ≤ 0.01. 
B16F10 n = 4, SK-Mel-28 n = 8, 
human melanoma n = 8
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SK-Mel-28 tumour model. Analysis of human samples 
showed a significant expression of CD31, while a diffuse 
and low expression of desmin has been found.
In the present study, two protocols have been used to 
induce mice melanoma. A first model was obtained follow-
ing the xenograft of 3.106 SK-Mel-28 cells in nude mice 
for 42 days. In this tumour model, a slow tumour growth 
reaching a volume of 100  mm3 in 21 days has been observed. 
These data are different from those obtained with a second 
B16F10 tumour model. In this case, only  106 B16F10 mela-
noma cells are sufficient to induce tumours, whose volume 
reaches 100  mm3 after 7 days. Furthermore, as shown in 
Fig. 1, mortality is significantly enhanced in mice allo-
grafted with B16F10 melanoma, in comparison with mice 
inoculated with SK-Mel-28. These results can be explained 
by differences in selected cell models. First, B16F10 cells 
have a significantly lower doubling time than the SK-Mel-28 
cells: 17.2 h (Danciu et al. 2013) for B16F10 vs 72 h for 
SK-Mel-28 cells (Wahl et al. 2002). Moreover, the analysis 
of VEGF expression by these both cell models showed that 
melanoma model induced by SK-Mel-28 cells expressed 
much less VEGF (Kim et al. 2009) than by B16F10 cells 
(Danciu et al. 2015). Thus, all of these data suggest that 
B16F10 cells are more aggressive than SK-Mel-28 cells, 
explaining the differences in tumour growth observed from 
these melanoma models.
As described by a multivariate analysis, tumour vascu-
larity, even more than the tumour thickness, is the most 
important determinant of its overall growth (Kashani-Sabet 
et al. 2002). Thus, as for all solid tumours, melanoma growth 
needs a high angiogenic activity, an important step in mela-
noma metastasis (Elder et al. 1996; Tuthill and Reed 2007). 
Angiogenesis is a dynamic process that involves different 
stages and, in particular, the activation of endothelial cells 
to form new vessels. These abnormal tumour vessels are 
characterized by a mal-shaped, irregular, disorganized, and 
tortuous architecture with a highly dysfunctional and leaky 
endothelial cell layer (De Bock et al. 2009, 2011; Jain 2005). 
In the present study, confocal microscopy revealed a low 
expression of CD31 expression in each tumour model. This 
finding suggests the existence of structural abnormalities 
in tumour endothelium from mice models as previously 
described in B16F10 by Duncan et al. (2013).
Immunolabeling data revealed very few (if any) expres-
sion of pericytes at the surface of tumour vessels from 
B16F10. While a greater expression of pericytes has been 
found at the surface of vessels from SK-Mel-28, only half 
of the identified vessels significantly expressed desmin, the 
Fig. 4  Confocal microscopy of a, b B16F10 and c, d SK-Mel-28 
tumour sections at a magnificence of 60X. e Microscopy of human 
tumour sections at a magnificence of 10X. a–c Endothelial cells were 
labelled with CD31 antibodies (green), b–d pericytes were labelled 
with desmin (red). Nuclei were labelled with DAPI (blue). Scale bar: 
20 µm. e Pericytes, showed by the arrow, were labelled with desmin 
and were revealed through peroxidase. Scale bar: 150 µm
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other half did not express it. These findings suggest that 
for fast-growing tumour models (such as B16F10), vascular 
patterning is incomplete, whereas for slow-growth models 
(as SK-Mel-28), the vessels appear to be better structured 
and organized and may be more impermeable than vessels 
from B16F10.
A limitation in the experimental design could have been 
the inequitable use of C57BL/6 mice for B16F10 tumours 
vs the use of nude mice for SK-Mel-28 tumours. Given the 
importance of the overall tumour micro-environment for 
controlling various steps of tumorigenesis (Palazon et al. 
2017), it would have been difficult to make comparisons 
on the two different tumours using two different hosts. For 
instance, while the immune compromised nude mice still 
possess innate immunity, they are deficient in components 
of acquired immunity. Since regulatory T cells and gamma-
delta T cells have both been implicated in promoting tumour 
vascularization (Fleming et al. 2017), the nude hosts will be 
deficient in this aspect of tumours blood vessel development. 
For these reasons, and because the vasculature is derived 
from the host rather than the tumour, we evaluated vascular 
density and tumour vessels’ structure in human melanoma 
models collected from immunocompetent patients. Thus, we 
have reported a vascular density identical to what found in 
SK-Mel-28 model but which proves not to be significantly 
different from what observed for B16F10 model. These data 
suggest that immune defect observed in nude mice cells does 
not influence microvascular density, as it may have been 
reported for some human primary oral melanoma by Simon-
etti et al. (2013). Microscopic analyses confirm an anarchic 
organization of human tumour vessels, characterized by 
a low expression of CD31 and a very weak expression of 
desmin. The analysis of the vascularization, according to the 
lumen size confirms the presence of capillaries, with a small 
caliber (10–103 µm2) in these samples. These findings have 
been reported in primary cutaneous melanomas of the scalp 
and neck, in which it has been found a correlation between 
melanoma growth and both vessel invasion and higher den-
sity (Pasquali et al. 2015).
The enhanced permeability and retention (EPR) effect 
is defined as a process of extravasation of large molecules 
from leaky tumour vasculature, leading to accumulation 
in tumour tissue (Matsumura and Maeda 1986). Newly 
formed blood vessels typically occur in higher density in 
tumour tissue (Vakoc et al. 2009), they often lack a smooth 
muscle layer and pericytes (Nagy et al. 2009), they have 
large lumen and wider fenestrations (Hashizume et al. 
2000), and they typically contain malfunctioning endothe-
lial cells (Dudley 2012). In addition, vascular perfusion 
tends to be impaired, at least to some extent, and blood 
flow is sluggish (Hori et al. 1991, 2000). Several of these 
features are described in our study mainly in the B16F10 
model compared to the SK-Mel-28 or human model. 
Based on these data and results, we could hypothesize 
that B16F10 melanoma model presents a more pronounced 
EPR effect than SK-Mel-28 or human model.
Several authors have described the EPR effect as 
essential for improving tumour-targeting of therapeutics 
(Stylianopoulos and Jain 2015; Taniguchi et al. 2003). For 
instance, it has been reported for Doxil®, the first FDA-
approved nanodrug, that it is passively targeted to tumours 
through the potentiation of EPR effect (Barenholz 2012). 
Thereby, the high permeability of tumour blood vessels 
would induce an important fluid loss from the vessel to 
the interstitial space, which could reduce tumour perfusion 
and further enhance the delivery of nanoparticles (Danhier 
et al. 2015; Stylianopoulos and Jain 2013).
However, these encouraging data should not mask the 
limitations of the therapeutic distribution through EPR 
effect. Thus, the theories described above are not sufficient 
(Hollis et al. 2013), because authors hypothesized that the 
EPR effect would restrict the delivery of various drugs, 
mainly in human tumours (Jain 2001; Jain and Stylianop-
oulos 2010). While using the EPR effect as a rationale for 
nanoparticles, it is often overlooked that not all tumour 
vessels are leaky, which causes a heterogeneous distribu-
tion of pore sizes and thus heterogeneous extravasation 
and delivery. Moreover, the permeability in tumour models 
depends on the transplantation site and varies with time 
and in response to treatment. Because tumours are usu-
ally faster-growing in animal models, it is to be expected 
that they will have a higher degree of vascularization and 
a less developed vascular environment, leading to a high 
EPR effect (Bolkestein et al. 2016). Therefore, it has been 
suggested by various authors (Lammers et al. 2012) and 
recently by Danhier (2016) that the EPR effect would be 
different in rodents than in humans. On one hand, human 
tumours develop usually from a cell or small group of 
cells, and it can take years before these cells develop a 
set of mutations required to escape from the immune sys-
tem and form tumour (Kim et al. 2007). This period lets 
tumour cells interact with surrounding cells and develop 
a highly heterogeneous and complex micro-environment 
(Egeblad et al. 2010). Furthermore, tumours are composed 
of heterogeneous cells containing subpopulations with 
various mutations, giving a diversity of mutated cells and 
resistance to treatment (Choi et al. 2011). On the other 
hand, unlike human tumours, animal models are usually 
obtained by implantation of a large number of tumour 
cells, growing generally in few weeks. Due to this fast 
growth, tumour cells can escape to the immune system and 
are not willing to develop the genetic diversity observed 
in natural human tumours. It seems that these differences 
have implications on the structure of tumour vessels, and 
therefore, they impact the leakage of macromolecules or 
nanomedicines.
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Our present study seems to confirm this hypothesis and 
suggests that human melanoma develop anarchic capillar-
ies to bring oxygen and nutrients to the tumour, while mice 
models have anarchic vessels with high lumen size probably 
more permeable to macromolecules or drugs. The highly 
variable nature of tumour models, which is a result of vari-
ous genetic mutations (and whose development conditions 
are different), leads to an enormously high heterogeneity in 
the vascularization of tumours, in the EPR effect on these 
tumours, and, therefore, in the anti-tumour responses of 
therapeutic agents. Our study confirms that, when aiming 
to develop nanomedicines for clinical use, the heterogene-
ity of vascularization and the EPR effect has to be taken 
into account and both combining studies on various models 
and new strategies have to be developed to overcome this 
obstacle.
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